Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors

Human Gene Therapy Methods

Volumn 26, Issue 6, 2015, Pages 228-242

  Burnham, Brenda ^a   Nass, Shelley ^a   Kong, Elton ^a   Mattingly, MaryEllen ^a   Woodcock, Denise ^a   Song, Antonius ^a   Wadsworth, Samuel ^a,b   Cheng, Seng H ^a   Scaria, Abraham ^a   O'Riordan, Catherine R ^a  

^a SANOFI   (France)

^b ULTRAGENYX PHARMACEUTICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR;

ANALYTIC METHOD; ARTICLE; COMPUTER PROGRAM; GENOME SIZE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; QUALITY CONTROL; REFRACTOMETRY; SEDIMENTATION; ULTRACENTRIFUGATION; VIRAL GENE THERAPY; VIRION; VIRUS DETECTION; VIRUS GENOME; VIRUS PARTICLE; VIRUS RECOMBINANT; CELL CULTURE TECHNIQUE; CELL LINE; DEPENDOPARVOVIRUS; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; ION EXCHANGE CHROMATOGRAPHY; ISOLATION AND PURIFICATION; PLASMID; PROCEDURES; REPORTER GENE; STANDARDS; TRANSGENE; VIRUS REPLICATION;

CELL CULTURE TECHNIQUES; CELL LINE; CHROMATOGRAPHY, ION EXCHANGE; DEPENDOVIRUS; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HUMANS; PLASMIDS; TRANSDUCTION, GENETIC; TRANSGENES; ULTRACENTRIFUGATION; VIRUS REPLICATION;

EID: 84949634261     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2015.048     Document Type: Article

References (50)

1. Hauswirth WW, Alemean TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to a RPE65 mutation by ocular subretinal injection of adeno-associated virus gene vector short-term results of a phase I trial. Hum Gene Ther 2008; 19:979-990.
2. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual frunction in Leber's congenital amaurosis. N Engl J Med 2008;358: 2231-2239.
3. Cideciyan AV, Aleman T, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow kinetics. Proc Natl Acad Sci USA 2008;105:15112-15117.
4. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis-persistence of early visual improvements and safety at 1 year. Hum Gen Ther 2009; 20:999-1004.
5. Cideciyan AV, Hauswirth W, Aleman TS, et al. Vision 1 year after gene therapy for Leber's congenital amaurois. N Engl J Med 2009;361:725-727.
6. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;398:2240-2248.
7. Maguire AM, High KA, Aurricchio A, et al. Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase I doseescalation trial. Lancet 2009;374:1597-1605.
8. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18:643-650.
9. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector mediated gene transfer in hemophilia B. N Engl J Med 2011;346: 2357-2365.
10. Yla-Herttuala S. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther 2010; 20:1831-1832.
11. Ayuso E, Mingozzi F, Bosch F. Production, purification and characterization of adeno-associated vectors. Curr Gene Ther 2010;10:423-436.
12. Berkowitz SA, Philo J. Monitoring the homogeneity of adenovirus preparations (a gene therapy delivery system) using analytical ultracentrifugation. Anal Biochem 2007;362:16-37.
13. Yang X, Agarwala S, Ravindran S, et al. Determination of particle heterogeneity and stability of recombinant adenovirus by analytical ultracentrifugation in CsCl gradients. J Pharm Sci 2006;97: 746-763.
14. Zhao H, Brautigam CA, Ghirlando R, Schuck P. Overview of current methods in sedimentation velocity and sedimentation equilibrium analytical ultracentrifugation. Curr Protoc Protein Sci 2013; 20.12.1-20.12.49.
15. Schuck P. Size Distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J 2000;78:1606-1619.
16. Philo JS. Analytical ultracentrifugation. In: Methods for Structural Analysis of Protein Pharmaceuticals. W Jiskoot, D Crommelin, eds. (AAPS, New York, NY). 2005; pp. 379-412.
17. Calabretta M, Jamison JA, Falkner JC, et al. Analytical ultracentrifugation for characterizing nanocrystals and their bioconjugates. Nano Lett 2005;5:963-967.
18. Zhou CM, Zhang GX, Ma XX. Characterization and evaluation of the immune responses elicited by a novel human papillomavirus (HPV) therapeutic vaccine: HPV16E7-HBcAg-Hsp65 fusion protein. J Virol Methods 2014;191-196.
19. Srivastava A, Lusby EW, Berns KI. Nucleotide seqeunce and organization of the adeno-assocaited virus 2 genome. J Virol 1983;45:555-564.
20. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsids formation in the nucleolus. Proc Natl Acad Sci USA 2010; 107:10220-10225.
21. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free optically controllable and two plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003;7: 839-850.
22. Matsushita T, Elliger S, Elliger C, et al. Adenoassociated virus vectors can be efficiently porduced without helper virus. Gene Ther 1998;5:938-945.
23. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72: 2224-2232.
24. King JA, Dubielzig R, Grimm D, etal. DNA helicasemediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J 2001;20:3282-3291.
25. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002;13:1935-1943.
26. Urabe M, Nakakura T, Xin K, et al. Scalable generation of high titer recombinant adeno-associated virus type 5 in insect cells. J Virol 2006;80:1874-1885.
27. Smith RH, Levvy J, Kotin RM. A simplified baculovirus AAV expression vector system coupled with one step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 2009;17:1888-1896.
28. Chen H. Intron splicing mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. Mol Ther 2008;16:924-930.
29. Hwang KK, Mandell T, Kintner H, et al. High titer recombinant adeno-associated virus production using replication deficient herpes simplex virus type I. Mol Ther 2003;7:S14-S15.
30. Kang W, Wang L, Harrell H, et al. An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther 2009;16:229-239.
31. Clark KR, Voulgaropoulou F, Folet DM. et al. Cell lines for the production of recombinant adenoassociated virus. Hum Gene Ther 1995;6:1329-1341.
32. Gao GP, Qu G, Faust LZ, et al. High-titer adenoassociated viral vectors from a rep/cap cell line and hybrid shuttle virus. Hum Gene Ther 1998;9: 2352-2362.
33. Chadeuf G, Favre D, Tessier J, et al. Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus induced amplification of the integrated rep-cap-genome. J Gene Med 2000;2:260-268.
34. Farson D, Harding TC, Tao L, et al. Development and characterization of a cell line for large scale, serum free production of recombinant adenoassociated viral vectors. J Gene Med 2004;6:1369-1381.
35. Thorne BA, Takeya RK, Peluso RW. Manufacturing recombinant adeno associated viral vectors from producer cell lines. Hum Gene Ther 2009;20:707-714.
36. Yuan Z, Qiao C, Hu P, et al. A versatile adenoassociated virus vector producer cell line method for scaleable vector production of different serotypes. Hum Gene Ther 2011;22:613-624.
37. Martin J, Frederick A, Luo Y, et al. Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. Hum Gene Ther Meth 2013;24:253-269.
38. Satkunanathan S, Wheeler J, Thorpe R, et al. Establishment of a novel cell line for the enhanced production of recombinant adeno-associated virus vectors for gene therapy. Hum Gene Ther 2014;25: 1-13.
39. Gao K, Li M, Zhong L, et al. Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects. Mol Ther Meth Clin Dev 2014;1: 9-13.
40. McCarty DM, Monahan PE, Samulski RJ. Self complementary recombinant adeno-associated virus (scAAV) vectors promote efficienct transduction independently of DNA synthesis. Gene Ther 2001;16:1248-1254.
41. De La Maza LM, Carter BJ. Heavy and light particles of adeno associated virus. J Virol 1980;33: 1129-1137.
42. Qu G, Bahr-Davidson J, Prado J, et al. Separation of adeno-assocaited virus type 2 empty particles from genome containing vector by anion-exchange chromatography. J Virol Methods 2007;140:183-192.
43. Sommer JM, Smith PH, Parthasarathy S, et al. Quantification of adeno-assocaited virus particles and empty capsids by optical density measurement. Mol Ther 2003;7:122-128.
44. Hauck B, Murphy SL, Smith PH, et al. Undetectable transcription of cap in a clinical AAV vector: Implications for preformed capsid in immune responses. Mol Ther 2009;17:144-152.
45. Chadeuf G, Ciron C, Moullier P, et al. Evidence for encapsidation of prokaryotic sequences during recombinant adeno-assocaited virus production and their in vivo persisitence after vector delivery. Mol Ther 2005;12:744-753.
46. Wu JW, Zhao L, Zhang Z, et al. Self-complementary recombinant adeno-assocaited viral vectors: packaging capacity and the role of the rep proteins in vector purity. Hum Gene Ther 2007;18:171-182.
47. Zeltner N, Kohlbrenner E, Clement N, et al. Nearperfect infectivity of wild type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther 2010;17:672-679.
48. Kapranov P, Chen L, Dederich D, et al. Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther 2012;23:46-55.
49. Horowitz ED, Rahman KS, Bower BD, et al. Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. J Virol 2013;87:2994-3002.
50. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.